News
News detail
First-in-Class Factor B Inhibitor LNP023
Source:
|
Author:EnzymeWorks
|
Published time: 2021-01-21
|
2746 Views
|
Share:
LNP023 is a first-in-class, potent and highly selective factor B inhibitor of the alternative complement pathway, and positive results from Phase II studies recently announced by Novartis. A novel chemoenzymatic process was developed by applying an enzyme from EnzymeWorks: https://newdrugapprovals.org/2020/03/11/lnp-023/
ISO 9001:2008 certified
COPYRIGHT © 2014 EnzymeWorks, Inc. ALL RIGHTS RESERVED